### 1 Title

2 A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination analysis

3

## 4 Short title

5 COVID-19 impact on HPV vaccination

6

# 7 Authors

8 Louiza S Velentzis<sup>1,2‡</sup>, Megan A Smith<sup>1‡</sup>\*, James Killen<sup>1</sup>, Julia Brotherton<sup>2,3</sup>, Rebecca Guy<sup>4</sup>, Karen Canfell<sup>1</sup>

9

- 11
- 12

13 1. Daffodil Centre, The University of Sydney, a joint venture with CCNSW, Sydney Australia;

- 14 2. School of Population and Global Health, University of Melbourne, Victoria, Australia
- 15 3. Australian Centre for Prevention of Cervical Cancer, Melbourne, Victoria, Australia
- 16 4. The Kirby Institute, University of New South Wales, Sydney, Australia
- 17
- 18
- 19 \*Corresponding author
- 20 A/Prof Megan A Smith, PhD
- 21 The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Australia.
- 22 Megan.Smith@nswcc.org.au
- 23 T:+61293341445

### 24 Abstract

- 25
- 26 COVID-19 disrupted school attendance in many countries, delaying routine adolescent vaccination against
- 27 human papillomavirus (HPV) in some settings. We used the 'Policy1-Cervix' HPV model (natural
- 28 history/vaccination/screening/HPV-related cancers), to estimate the impact on HPV-related cancers from
- 29 disruptions to HPV vaccination in a high-income setting. Compared to no disruption (nonavalent vaccine
- 30 uptake, age 12 [females:82.4%; males:75.5%] as in Australia), additional lifetime HPV-related cancer cases were
- 31 calculated for three disruption scenarios affecting one birth cohort (2008): i) 1-year delay (no doses missed); ii)
- 1 to 7-year delay (slow catch-up); iii) no catch-up (herd effects only). A fourth scenario assumed no catch-up for
- 33 two cohorts (2008,2009). We found a 1-year delay could result in ≤0.3% more HPV-related cancers (n=4) but
- 34 the increase would be greater if catch-up was slower (5%; n=70), and especially if there was no catch-up (49%;
- n=750). Additional cancers for a single missed cohort were most commonly cervical (23%), oropharyngeal
- 36 (males:20%) or anal (females:16%). In the worst-case scenario of two cohorts missing vaccination, ≤62% more
- 37 HPV-related cancers would be diagnosed (n=1,892). In conclusion, providing catch-up of missed HPV vaccines is
- 38 conducted, short-term delays in vaccinating adolescents are unlikely to have substantial long-term effects on
- 39 cancer.

#### 40 Introduction

- 41 Australia was the first country to implement a fully-government funded National HPV Vaccination program.
- 42 HPV vaccination has been routinely offered through schools, to girls aged 12–13 years since 2007 and to boys
- 43 aged 12-13 years since 2013 (plus catch-up for females aged 14 to 26 years in 2007-2009 and for males age 14-
- 15 in 2013-2014). In 2018, a three-dose schedule with the quadrivalent HPV vaccine which protects against
- 45 four HPV types (6, 11, 16 and 18), was replaced by a two-dose schedule with the nonavalent HPV vaccine
- 46 (HPV9), protecting against an additional five oncogenic HPV types (31, 33, 45, 52 and 58). Since 2017, free
- 47 catch-up of vaccinations under the Australian National Immunization Program, including the HPV vaccine, is
- 48 available to all people aged under 20 years and is administered in primary care.<sup>1</sup> HPV course completion rates
- 49 by age 15 were 79.8 % among girls and 77.0% among boys who reached the age of 15 years in 2019.<sup>2</sup>
- 50
- 51 Following the World Health Organization's declaration of the COVID-19 pandemic in March 2020, strict national
- 52 and state-level infection control measures were introduced in Australia. Social and physical restrictions
- affected essential health services including the delivery of school-based vaccination programs due to school
- closures from imposed lockdowns in 2020 and in some states in 2021.<sup>3,4</sup> Globally, the World Health
- 55 Organization reported the largest continued decline in overall vaccinations in the last three decades and a loss
- 56 of over a quarter of the HPV vaccine coverage achieved in 2019.<sup>5</sup>
- 57
- 58 Infection with oncogenic HPV types is a major causal factor for the development of cervical cancer and for a
- 59 fraction of cancers of the anus, oropharynx, penis, vagina, and vulva.<sup>6</sup> Except for cervical screening, organized
- 60 screening is not generally available for any of the other HPV-related cancers. A previous analysis of the burden
- of HPV-related disease in Australia estimated that 80% of the estimated 1,544 HPV-associated cancers in 2012
- 62 were attributable to types preventable by the quadrivalent vaccine (HPV16/18), with an additional 9%
- 63 attributable to the five additional types prevented by the nonavalent vaccine.<sup>7</sup>
- 64
- The aim of this study was to estimate the additional lifetime HPV-related cancer cases in men and women that could be caused by HPV vaccination delays or missed doses due to the pandemic by using a simulation model
- 67 to project the long-term outcomes from different potential disruption scenarios, using Australia as an example.
- The study was designed prior to the emergence of actual 2020-21 vaccination disruption data, and hence, a
- 69 number of potential disruption scenarios were considered to encompass a wide range of possibilities.
- 70

# 71 Methods

# 72 Model

- 73 We used Policy1-Cervix, an established modelling platform of dynamic HPV transmission, HPV natural history,
- recrvical screening, treatment and cancer survival that has been validated across several settings. The dynamic
- 75 HPV transmission component of Policy1-Cervix incorporates HPV vaccination and was used to estimate HPV
- 76 incidence by age under scenarios of disruption to vaccination coverage compared to a no disruption scenario.
- 77 The number of lifetime cervical cancer cases was subsequently estimated for the cohorts affected after
- explicitly modelling cervical screening (5-yearly HPV screening starting from age 25)<sup>8</sup> to take into account that
- 79 cervical screening may prevent some cancers that would otherwise have been prevented by vaccination. In
- 80 addition, HPV incidence estimated by the dynamic HPV transmission model was used in a separate incidence-
- based model to project the lifetime number of non-cervical HPV-related cancers in both sexes (i.e., anal,
- 82 oropharyngeal, penile, vaginal, vulvar), as previously described.<sup>9</sup> Data included age- and sex-specific incidence
- 83 of each cancer and proportion of cases attributable to vaccine-targeted HPV types (Supplementary Files 1A, 1B,
- 1C). In a sensitivity analysis, we also used an analogous incidence-based approach to also estimate the impact
- 85 on cervical cancer, rather than explicitly allowing screening to prevent some of the cervical cancers which

would arise due to missed vaccination. Further information on the Policy1-Cervix model can be found at
 <a href="https://www.policy1.org/models/cervix/documentation">https://www.policy1.org/models/cervix/documentation</a>.

88

#### 89 Scenarios

90 A baseline scenario of uninterrupted HPV vaccination (status quo) assumed a 2-dose uptake of HPV9 at age 12

- 91 of 82.4% among females and 75.5% among males. Three disruption scenarios were modelled affecting the 2008
- 92 birth cohort who were aged 12 in 2020 (322,115 people). Scenario 1 assumed a fast catch-up where
- vaccination was delayed by one year (but no doses were entirely missed); scenario 2 assumed a slow catch-up
- 94 where vaccination was delayed between 1 and 7 years with an equal proportion being caught up each year;
- and scenario 3 assumed there was no catch-up, and therefore any protection in the cohort would be due to
- 96 herd effects only. A fourth scenario was also conducted which assumed disruption to HPV vaccination for two
- birth cohorts (cohort of 2008 and 2009) (644,230 people), with no catch-up.
- 98
- 99 For each scenario we estimated the number of HPV-associated cancer cases (from age 12 to 84 years)
- 100 prevented by vaccination compared to an unvaccinated comparator cohort, and the additional number of cases
- 101 under each disruption scenario compared to the no disruption scenario.
- 102

### 103 **Results**

104 In the baseline scenario, we estimate 2,583 HPV-related cancer cases would be prevented in the 2008 cohort

- 105 due to HPV vaccination, equating to 63% of all HPV-related cases (Table 1). The first disruption scenario (1-year
- delay) would result in 4 (0.3%) additional lifetime cancer cases and slightly fewer cases prevented overall
- 107 (2,579). Under a slow vaccination catch-up strategy or in the worse cases no vaccination catch-up for either
- one or two cohorts an additional 70 (5%), 750 (49%) and 1892 (62%) cancer cases, respectively, were
   predicted to occur.
- 110

111 Table 2 shows a breakdown of HPV-related cancer cases developed over a lifetime by cancer type and sex for 112 the disruption scenarios. In the worst-case scenarios of missed HPV vaccination, most of the additional cancers 113 occurred in females, and the additional cancers were most commonly cervical and anal cancers (females) and

oropharyngeal, followed by anal cancers (males). When combined across both sexes, the additional cancers

- were most commonly oropharyngeal (>80% of which were in males) and anal cancers (mostly in females).
- 116 In the main analysis, we explicitly modelled primary HPV cervical screening as also occurring in these cohorts,
- which would allow the cervical screening program to compensate, to some extent, for cervical cancers not prevented via HPV vaccination. In the sensitivity analysis that used an incidence-based approach, the number
- of additional cervical cancer cases predicted was larger and cervical cancers would have comprised around 35%
- 120 of the additional HPV-related cancer cases (rather than around 17-25%, when screening was modelled)
- 121 (Supplementary File 1D). The percentage increase in cases was similar but somewhat higher (for example 54%
- increase in cases for one missed cohort, compared to 49% increase when screening was modelled).

# Table 1: Estimated number of HPV-related cancer cases and cases prevented for vaccinated and unvaccinated cohorts, and four vaccination disruption scenarios.

125

	Affected Cohort (2008)						Affected Cohorts (2008 and 2009)					
Modelled scenarios	Total Cases	Prevented Cases (Unvax Comparator)	Additional Cases (Compared to No disruption)	% Prevented (Unvax Comparator)	% Additional (Compared to No disruption)	Total Cases	Prevented Cases (Unvax Comparator)	Additional Cases (Compared to No disruption)	% Prevented (Unvax Comparator)	% Additional (Compared to No disruption)		
Unvaxed No	3,923					7,847						
disruption S1: 1 y	1,532	2,583		63%		3,061	4,876		63%			
delay S2: 1 to 7v	1,537	2,579	4	63%	0.3%	3,066	4,781	5	63%	0.2%		
delay S3: no	1,603	2,513	70	61%	5%	3,133	4,714	72	62%	2%		
catch-up S4: no catch-up (2 missed	2,282	1,833	750	45%	49%	3,846	4,001	785	53%	26%		
cohorts)	2,503	1,613	970	39%	63%	4,954	2,893	1892	40%	62%		

126 Abbreviations: vax: vaccine; unvaxed: unvaccinated (i.e. assuming no HPV vaccination in cohort(s).

127 No disruption: status quo HPV vaccination in males and females at age 12; scenario 1: rapid catch-up, 1-year delay in HPV vaccine catch-up; scenario 2: slow catch-up, 1 to 7-year delay in

128 HPV vaccine catch-up; scenario 3: no HPV vaccine catch-up (herd effects only 2008 cohort); scenario 4: no HPV vaccine catch-up (herd effects only; 2008 and 2009 cohorts).

	Total Cases (additional	Females, N (additional compared to no disruption)					Males, N (additional compared to no disruption)		
Modelled scenarios	compared to no disruption)	Anal	Cervical	Oropharyngeal	Vaginal	Vulvar	Anal	Oropharyngeal	Penile
				2008 cohort					
Unvaxed	3,923	489	788	185	162	729	389	911	271
No disruption	1,532	100	62	86	61	580	74	423	146
				86	61	580			146
Scenario 1	1,537 (4)	101 (1)	63 (1)				75 (1)	424 (1)	
Scenario 2	1,603 (70)*	114 (14)	74 (12)	90 (4)	64 (3)	586 (6)	85 (11)	440 (17)	150 (4)
Scenario 3	2,282 (750)*	236 (136)	250 (188)	121 (35)	96 (35)	632 (52)	175 (101)	593 (170)	180 (34)
			20	08 and 2009 coho	rts				
Unvaxed	7,847	978	1,576	370	324	1458	778	1822	542
No disruption	3,061	199	125	172	122	1160	148	845	292
Scenario 4									
2008 cohort	2,503 (971)*	276 (176)	303 (241)	131 (45)	107 (46)	647 (67)	205 (131)	644 (221 <u>)</u>	190 (44)
2009 cohort	2,451 (922)	268 (169)	285 (222)	129 (43)	104 (43)	644 (64)	199 (125)	634 (212)	188 (42)
Scenario 4 total	4,954 (1,892)*	544 (345)	588 (463)	260 (88)	211 (89)	1,291 (131)	404 (256)	1,278 (433)	378 (86)

#### 129 Table 2: Estimated number of cancer cases in modelled scenarios according to sex and cancer type.

130

131 \*The number of additional cases presented in the table do not always match the difference between case figures stated for individual scenarios in table 2, due to rounding.

132 Unvaxed: assuming no HPV vaccination in cohort (s); No disruption: HPV vaccination in males and females at age 12 with coverage of 82.4% in females and 75.5% in males; scenario 1: 133 rapid catch-up, 1-year delay; scenario 2: slow catch-up, 1 to 7-year delay; scenario 3: no catch-up (herd effects only 2008 cohort); scenario 4: no catch-up (herd effects only; 2008 and

134 2009 cohorts.

135 Sum of cases may not add to 'total cases' due to rounding.



137 138

136

.38 S: scenario; y: year.

Figure 1: Estimated lifetime HPV-related cancer cases from two HPV vaccination catch-up scenarios [(1-year
delay in vaccination (rapid); 1 to 7 year delay in vaccination (slow)] and two scenarios modelling the absence of
vaccination catch-up, varying in the cohort affected (scenario 3 affecting the 2008 birth cohort; scenario 4
affectioning the 2008 and 2009 birth cohorts).

144

145

# 146 **Discussion**

147 This is the first study to estimate the long-term potential impact of missed HPV vaccinations across HPV-

148 induced cancers while accounting for natural history, sexual behaviour and herd immunity. We found that

rapid catch-up of HPV vaccination in young adolescents within a year meant that even extreme disruptions

150 where all vaccinations were delayed had a minimal long-term effect on cancer cases. A slower pace of

151 recovery, however, or, in the worst case, missed vaccination in one or two cohorts was associated with a higher

152 excess burden of cancers. While herd effects from vaccination still prevented close to half of HPV-related

153 cancers, missing a single cohort entirely would result in an estimated 49% more HPV-related cancers in that

- 154 cohort compared to no disruption.
- 155
- 156 In Australia, for adolescents aged 11 to <15 years who received their first dose in 2020, 74.7% of girls and
- 157 72.6% of boys, nationally, received their second dose in the same calendar year as their first dose.<sup>2</sup>
- 158 Corresponding figures for 2019, for the second dose, were 86.2% and 84.3%, for girls and boys respectively.<sup>2</sup>
- 159 The difference in numbers suggest vaccination delays, possibly due to COVID-19 effects including school
- 160 closures during lockdowns, and decreased school attendance due to infections. Reports from other countries
- 161 indicate that COVID-19 has delayed progress in achieving high coverage of HPV vaccination. For example, a US

study found recovery after a marked decline in HPV dose administration in March to May 2020 (median 64% 71%) was not fully achieved during June-September 2020.<sup>10</sup>

164

165 In November 2020 WHO released a global strategy calling for all countries to take action to achieve the elimination of cervical cancer as a public health problem within the next century.<sup>11</sup> In the near future most 166 167 lives will be saved globally through increased uptake of cervical screening and access to cancer treatment (Canfell 2020), but in the longer-term maintaining high coverage of HPV vaccination will be critical in reducing 168 mortality and achieving global elimination.<sup>12,13</sup> Globally, the timeframe to reach elimination is likely to be 169 170 impacted by pandemic-induced delays in HPV vaccination delivery and also by global shortages of the HPV 171 vaccine estimated to last until 2024 thus delaying the introduction of vaccination in low- and middle-income 172 countries.<sup>14</sup> In countries predicted to achieve cervical cancer elimination in the relatively short term, such as Australia, short delays of one year are not predicted to delay elimination.<sup>8</sup> 173

174

175 The strengths of this study include evaluating the impact of the COVID-19 pandemic across different HPV-

- 176 related cancers, in both women and men and across a wide range of possibilities for vaccination disruption -
- 177 two of which assumed a delay in HPV vaccination and two scenarios where the affected birth cohorts remained
- 178 unvaccinated. Some limitations should also be noted. Even in the context of some cohorts missing vaccination
- 179 entirely, herd effects still prevented a considerable proportion of HPV-related cancers overall; these effects
- 180 would be smaller in settings with lower coverage.<sup>15</sup> This is unlikely to affect our finding that catch-up within a
- 181 year minimises the impact of disruptions, and so would likely strengthen the case for rapid catch-up in settings
- 182 where herd effects are likely to be lower. The model also assumed that cervical screening would continue in
- birth cohorts offered HPV9, and, based on our sensitivity analysis that removed explicit modelling of screening,
- this prevented some cancers that would otherwise have occurred due to missed vaccination. In practice,
   screening may not continue in the same way in cohorts offered HPV9 as it would be much less cost-effective.<sup>16</sup>
- 186 As yet, no policy decision has been made for screening in these cohorts, however, and screening may in future
- 187 be tailored based on individual vaccination status, rather than age-eligibility for vaccination. The model did not
- 188 incorporate any potential changes in sexual behaviour which may affect estimates.
- 189

190 Our findings provide evidence that rapid catch-up of missed HPV vaccine doses would minimise the long-term

191 impact of vaccination program disruptions, but delays would result in preventable HPV-related cancer cases in

192 future.

#### 193 Competing Interests

194 MAS reports salary support via fellowship grants from the National Health and Medical Research Council

- 195 (NHMRC) of Australia (APP1159491) and Cancer Institute NSW (ECF181561) and contracts paid to her
- 196 institution (the Daffodil Centre) with the Commonwealth Department of Health (Australia) and National
- 197 Screening Unit (New Zealand). JMLB's former employer ACPCC has received donated HPV tests and
- related items for validation and research purposes from Roche, Seegene, Abbott, Becton Dickinson,
- 199 Cepheid and Copan. KC is co-PI of an investigator-initiated trial of cervical screening, "Compass", run by
- 200 the Australian Centre for Prevention of Cervical Cancer (ACPCC), which is a government-funded not-for-
- 201 profit charity. Compass receives infrastructure support from the Australian government and the ACPCC
- 202 has received equipment and a funding contribution from Roche Molecular Diagnostics, USA. KC is also
- 203 co-PI on a major implementation program Elimination of Cervical Cancer in the Western Pacific which
- has received support from the Minderoo Foundation and the Frazer Family Foundation and equipment
- 205 donations from Cepheid Inc. KC receives contract funding from Commonwealth Department of Health,
- Australia to her institution for work to monitor the safety of the National Cervical Screening Program. KC
- also receives support for a range of other Australian and international government projects including
- 208 support from philanthropic organizations, WHO, and government agencies related to cervical cancer
- 209 control. The remaining authors have no conflicts of interests to declare.

210

## 211 Data availability statement

212 Supporting information on data, data sources, model parametrization, calibration to epidemiologic data, and

- calibration approach in line with good modeling practice can be found partly in the supplementary materials
- for this article and partly on-line (<u>https://www.policy1.org/models/cervix/documentation</u>). The current
- 215 manuscript is a computational study involving modelling rather than direct analysis of primary datasets and no
- 216 new datasets have been created.
- 217
- 218 Code for the Policy1-cervix microsimulation model has been developed over decades, is proprietary property,
- and cannot be provided by the authors at this time. However, the Daffodil Centre is working to provide
- transparent and reproducible modelling code for forthcoming projects. Access to code is possible only through
- 221 appropriately resourced supervision at the Daffodil Centre after submission and approval of a detailed proposal
- by the interested researcher. The corresponding author should be contacted in the first instance.

# 223 References

1. Australian Government Department of Health and Aged Care. National Immunisation Program 224 225 Schedule: Government of Australia. [Accessed 5 August 2022]. 226 2. National Centre for Immunisation Research and Surveillance Australia. Annual Immunisation Coverage 227 Report 2020, 29 November 2021. (Accessed 8 August 2022). Available from: https://www.ncirs.org.au/sites/default/files/2022-228 07/NCIRS%20Annual%20Immunisation%20Coverage%20Report%202020.pdf 229 230 National Centre for Immunisation Research and Surveillance Australia. COVID-19 in schools and early 231 childhood education and care services – the experience in NSW: 16 June to 31 July 2021. (Accessed 8 232 August 2022). Available from: https://www.ncirs.org.au/sites/default/files/2021-233 09/NCIRS%20NSW%20Schools%20COVID\_Summary\_8%20September%2021\_Final.pdf 234 4. Parliament of Victoria. Chronology of primary and secondary school closures in Victoria due to COVID-235 19, 3 April 2021. (Accessed on 8 August 2022). Research papers. Available from:

236		https://www.parliament.vic.gov.au/publications/research-papers/send/36-research-papers/14000-
237		primary-and-secondary-school-closures-in-victoria-due-to-covid-19
238	5.	World Health Organization. COVID-19 pandemic fuels largest continued backslide in vaccinations in
239		three decades. 15 July 2022 (Accessed on 9 December 2022). Available from:
240		https://www.who.int/news/item/15-07-2022-covid-19-pandemic-fuels-largest-continued-backslide-in-
241		vaccinations-in-three-decades
242	6.	IARC monographs on the evaluation of carcinogenic risks to Humans. A review of human carcinogens.
243		Part B: Biological agents. Volume 100. Lyon, France: IARC; 2012. Accessed 9 August 2022. Available
244		from: <a href="https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono100B.pdf">https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono100B.pdf</a>
245	7.	Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, Marshall H. The impact of
246		10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a
247		nonavalent vaccine prevent? Euro Surveill. 2018 Oct;23(41):1700737. doi: 10.2807/1560-
248		7917.ES.2018.23.41.1700737.
249	8.	Smith MA, Burger EA, Castanon A, de Kok IMCM, Hanley SJB, Rebolj M, Hall MT, Jansen EEL, Killen J,
250		O'Farrell X, Kim JJ, Canfell K. Impact of disruptions and recovery for established cervical screening
251		programs across a range of high-income country program designs, using COVID-19 as an example: A
252		modelled analysis. Prev Med. 2021; 151:106623. doi: 10.1016/j.ypmed.2021.106623.
253	9.	Kim JJ, Simms KT, Killen J, Smith MA, Burger EA, Sy S, Regan C, Canfell K. Human papillomavirus
254		vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. PLoS Med.
255		2021;18(3):e1003534. doi: 10.1371/journal.pmed.1003534.
256	10.	Patel Murthy B, Zell E, Kirtland K, et al. Impact of the COVID-19 pandemic on administration of selected
257		routine childhood and adolescent vaccinations - 10 U.S. Jurisdictions, March-September 2020. MMWR
258		Morb Mortal Wkly Rep. 2021;70(23):840–845.
259	11.	World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public
260		Health Problem. November 2020. (Accessed 8 August 2022) Available from:
261		https://www.who.int/publications/i/item/9789240014107
262	12.	Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. Mortality impact of achieving
263		WHO cervical cancer elimination targets: A comparative modelling analysis in 78 low-income
264		and lower-middle-income countries. Lancet. 2020;395(10224):591-603.
265	13.	Brisson M, Kim JJ, Cantell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Bénard E, Boily
266		MC, Sy S, Regan C, Keane A, Caruana M, Nguyen DTN, Smith MA, Laprise JF, Jit M, Alary M, Bray
267		F, Fidarova E, Elsheikh F, Bloem PJN, Broutet N, Hutubessy R. Impact of HPV vaccination and
268		cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-
269	4.4	Income and lower-middle-income countries. Lancet. 2020;395(10224):575-590.
270	14.	world Health Organization (WHO). Global market study: HPV. Geneva: WHO; 2018. (Accessed
271	4 5	nttps://apps.wno.int/ins/nandle/10665/311275
272	15.	Brisson M, Benard E, Drolet M, Bogaards JA, Baussano I, Vanska S, Jit M, Bolly MC, Smith MA, Berkhol J,
2/3		Cameri K, Chesson HW, Burger EA, Chor FH, De Biasio BF, De Vias SJ, Guzzella G, Honleiez JAC, Horn J,
2/4 275		SP. Turner HC. Licher C. Walch C. Population-level impact hard immunity and elimination after human
213		papillomavirus vascinations a systematic roview and meta analysis of predictions from transmission
270 277		dynamic models. Lancot Dublic Hoalth. 2016:1(1):02 a17
277 278	16	Simme KT Smith MA Low IR Kitchener HC Castle DE Canfall K Will convice correspond remain
270 270	10.	cost-offective in women offered the peyt generation percevalent HDV/vaccine? Pecults for four
213		doveloped countries Int I Cancer 2016:120(12):2771.2790. doi: 10.1002/iic.20202
200		acverated contrines. Int a cancer 2010,133(12).21/1-2700. 001. 10.1002/1JC.30332.